Research Priorities for Expansion of Opioid Use Disorder Treatment in the Community Pharmacy
Substance Abuse · 2023-10 · 44 (4) · 264-276
DOI: 10.1177/08897077231203849 ↗Kurz gefasst
Fachartikel in der Zeitschrift Substance Abuse, online erschienen am 30.10.2023. Verfasst von Jennie B Jarrett und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice, College of Pharmacy, University of Illinois Chicago, Chicago, USA. Hauptthemen laut MEDLINE: Pharmacies, Pharmacy, Opioid-Related Disorders, Buprenorphine. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 115 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDA NIH HHS, National Drug Abuse Treatment Clinical Trials Network.
Themen: Sucht und Abhängigkeit
Abstract (Originalsprache)
In the last decade, the U.S. opioid overdose crisis has magnified, particularly since the introduction of synthetic opioids, including fentanyl. Despite the benefits of medications for opioid use disorder (MOUD), only about a fifth of people with opioid use disorder (OUD) in the U.S. receive MOUD. The ubiquity of pharmacists, along with their extensive education and training, represents great potential for expansion of MOUD services, particularly in community pharmacies. The National Institute on Drug Abuse’s National Drug Abuse Treatment Clinical Trials Network (NIDA CTN) convened a working group to develop a research agenda to expand OUD treatment in the community pharmacy sector to support improved access to MOUD and patient outcomes. Identified settings for research include independent and chain pharmacies and co-located pharmacies within primary care settings. Specific topics for research included adaptation of pharmacy infrastructure for clinical service provision, strategies for interprofessional collaboration including health service models, drug policy and regulation, pharmacist education about OUD and OUD treatment, including didactic, experiential, and interprofessional curricula, and educational interventions to reduce stigma towards this patient population. Together, expanding these research areas can bring effective MOUD to where it is most needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy Practice, College of Pharmacy, University of Illinois Chicago, Chicago, USA.
- Department of Pharmacy Practice and Clinical Research, College of Pharmacy, University of Rhode Island, Kingston, RI, USA.
- American Pharmacists Association, Washington, DC, USA (retired).
- Department of Internal Medicine, School of Medicine, University of Utah, Salt Lake City, UT, USA.
- Department of Practice, Sciences, and Health Outcomes Research, School of Pharmacy, University of Maryland Baltimore, Baltimore, MD, USA.
- American Society of Health-System Pharmacists, Washington, DC, USA.
ORCID-Profile: Jennie B Jarrett, Jeffrey Bratberg, Gerald Cochran, Lucas G Hill
Förderung
- NIDA NIH HHS
- National Drug Abuse Treatment Clinical Trials Network
Zitieren
APA
Jarrett, J. B., Bratberg, J., Burns, A. L., Cochran, G., DiPaula, B. A., Legreid Dopp, A., Elmes, A., Green, T. C., Hill, L. G., Homsted, F., Hsia, S. L., Matthews, M. L., Ghitza, U. E., Wu, L. T., & Bart, G. (2023). Research Priorities for Expansion of Opioid Use Disorder Treatment in the Community Pharmacy. Substance Abuse, 44(4), 264-276. https://doi.org/10.1177/08897077231203849
Vancouver
Jarrett JB, Bratberg J, Burns AL, Cochran G, DiPaula BA, Legreid Dopp A, et al. Research Priorities for Expansion of Opioid Use Disorder Treatment in the Community Pharmacy. Substance Abuse. 2023;44(4):264-276. doi:10.1177/08897077231203849
BibTeX
@article{Jarrett2023,
author = {Jarrett, Jennie B and Bratberg, Jeffrey and Burns, Anne L and Cochran, Gerald and DiPaula, Bethany A and Legreid Dopp, Anna and Elmes, Abigail and Green, Traci C and Hill, Lucas G and Homsted, Felicity and Hsia, Stephanie L and Matthews, Michele L and Ghitza, Udi E and Wu, Li-Tzy and Bart, Gavin},
title = {Research Priorities for Expansion of Opioid Use Disorder Treatment in the Community Pharmacy},
journal = {Substance Abuse},
year = {2023},
volume = {44},
number = {4},
pages = {264--276},
doi = {10.1177/08897077231203849}
}
EUVIMED